Physician profile
David E Steiner
NPI 1093896722
$12,951.30
in general payments reported to CMS, 2019-2025
48 companies · $3,010 in 2025
The $3,010 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,634 · 2020: $419 · 2021: $800 · 2022: $1,058 · 2023: $3,492 · 2024: $2,538 · 2025: $3,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $4,169 · Food and Beverage: $3,934 · Travel and Lodging: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $4,168.89 |
| Food and Beverage | $3,934.12 |
| Travel and Lodging | $937.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $5,299.11 | 2019-2025 | Venacure 1470 Pro |
| Janssen Research & Development, LLC | $1,227.20 | 2023 | |
| Pfizer INC. | $663.75 | 2019-2025 | |
| Novo Nordisk INC | $614.20 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $523.54 | 2019-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $487.92 | 2020-2023 | Gallant, Aveir |
| Boston Scientific Corporation | $441.19 | 2021-2025 | Watchman Flx, Watchman |
| Amgen INC. | $399.40 | 2020-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $391.87 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $271.79 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.56 | 2022-2023 | Jardiance |
| Exact Sciences Corporation | $251.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $233.85 | 2020-2025 | Eliquis, Camzyos |
| Medtronic Vascular, INC. | $169.81 | 2019 | |
| Janssen Pharmaceuticals, INC | $163.88 | 2019-2023 | Xarelto |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $127.43 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Cvrx, INC. | $119.48 | 2023-2025 | Barostim Neo System |
| Astellas Pharma US INC | $118.08 | 2019-2024 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $116.16 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $107.77 | 2019-2023 | Seglentis, Livalo |
| Heartflow, INC. | $107.04 | 2023-2025 | Ffrct |
| Medtronic, INC. | $86.07 | 2022-2025 | Venaseal |
| Becton, Dickinson and Company | $72.33 | 2024 | Venclose Maven Catheter |
| Esperion Therapeutics, INC. | $71.73 | 2021-2022 | |
| Horizon Therapeutics Plc | $60.71 | 2023 | Krystexxa |
| American Regent | $60.00 | 2024 | Injectafer |
| Kiniksa Pharmaceuticals, Ltd. | $41.85 | 2021-2022 | |
| Tactile Systems Technology INC | $41.68 | 2023-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Bayer Healthcare Pharmaceuticals INC. | $40.82 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $33.44 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $33.32 | 2019-2023 | Evkeeza |
| Lilly USA, LLC | $30.08 | 2024 | Mounjaro, Zepbound |
| Atricure, INC. | $29.12 | 2025 | Synergy Ablation System |
| Scpharmaceuticals INC. | $24.43 | 2023 | |
| Medicure Pharma INC. | $24.27 | 2025 | Zypitamag |
| Mylan Specialty L.P. | $23.32 | 2021 | |
| Agepha Pharma Fz LLC | $21.85 | 2024 | Lodoco |
| Bard Peripheral Vascular, INC. | $21.76 | 2025 | Venclose Maven Catheter |
| Alnylam Pharmaceuticals INC. | $19.70 | 2025 | Onpattro |
| Corcept Therapeutics | $18.27 | 2025 | Korlym |
| Abbvie INC. | $17.23 | 2023 | Synthroid |
| Grifols USA, LLC | $16.94 | 2025 | Prolastin-C Liquid |
| Dexcom, INC. | $16.63 | 2025 | Dexcom G6 Transmitter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.99 | 2022 | |
| Abiomed | $14.97 | 2024 | Impella |
| Currax Pharmaceuticals LLC | $13.81 | 2024 | Contrave |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Steiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.